Forte Biosciences, Inc. (FBRX) Financial Ratios
10 years of historical data (2015–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.45
-6% vs avg
5yr avg: 1.54
30Y Low0.4·High4.5
ROE
↑
-80.8%
-4% vs avg
5yr avg: -77.4%
30Y Low-145%·High-13%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
FBRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Forte Biosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $76M | $66M | $26M | $17M | $30M | $268M | $17M | $165M | $150M | — | — |
| Enterprise Value | $54M | $44M | $14M | $-23716475 | $-12152908 | $209M | $10M | $150M | $125M | — | — |
| P/E Ratio → | -2.15 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | 9.13 | 3651.84 | — | — |
| P/B Ratio | 1.45 | 1.26 | 0.73 | 0.45 | 0.72 | 4.54 | 2.93 | 2.83 | 2.11 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
FBRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | 8.32 | 3039.45 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
FBRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -80.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | — | — | — | — | — | — | — | -254.2% | -91778.0% | -64675.5% | -45007.8% |
| Net Profit Margin | — | — | — | — | — | — | — | -271.4% | -94948.8% | -68322.4% | -45207.8% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -80.8% | -80.8% | -84.9% | -34.5% | -43.2% | -143.6% | -12.7% | -75.8% | -99.7% | -145.3% | -59.0% |
| ROA | -70.6% | -70.6% | -77.7% | -32.5% | -41.5% | -134.9% | -7.3% | -50.2% | -61.1% | -68.7% | -37.1% |
| ROIC | -102.5% | -102.5% | -231.3% | — | — | — | -14.4% | -76.8% | -82.5% | -67.1% | -35.6% |
| ROCE | -83.4% | -83.4% | -87.6% | -34.6% | -42.7% | -44.0% | -8.8% | -56.9% | -78.6% | -82.1% | -40.8% |
FBRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $22M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | 0.45 | 0.15 | 3.00 | 0.45 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.42 | -0.34 | -1.06 | -1.01 | -1.00 | -1.21 | -0.25 | -0.35 | 2.21 | 0.24 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | -264.47 | -19.48 | — | — |
Net cash position: cash ($22M) exceeds total debt ($0)
FBRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Forte Biosciences, Inc.'s current ratio of 6.76x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 13.06x to 6.76x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.76 | 6.76 | 10.45 | 13.06 | 24.19 | 26.52 | 3.93 | 5.91 | 5.23 | 2.26 | 10.14 |
| Quick Ratio | 6.76 | 6.76 | 10.45 | 13.06 | 24.19 | 26.52 | 3.93 | 5.91 | 5.23 | 2.26 | 10.14 |
| Cash Ratio | 6.43 | 6.43 | 10.13 | 12.93 | 23.92 | 26.01 | 3.63 | 5.81 | 5.12 | 2.17 | 9.93 |
| Asset Turnover | — | — | — | — | — | — | — | 0.17 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
FBRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Forte Biosciences, Inc. returns 0.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | — | — |
| Shares Outstanding | — | $3M | $1M | $695341 | $558712 | $294357 | $84330 | $53492 | $38953 | $52738 | $48626 |
Peer Comparison
Compare FBRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 FBRXYou | $76M | -2.2 | — | — | — | — | -80.8% | -102.5% | — |
 ETON | $839M | -182.5 | — | 82.3 | 53.5% | -1.1% | -18.2% | -2.6% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 SLDB | $551M | -3.6 | — | — | — | — | -109.9% | -120.8% | — |
 TARS | $3B | -40.2 | — | — | 93.2% | -15.7% | -23.4% | -23.4% | — |
 NUVL | $8B | -17.5 | — | — | — | — | -36.7% | -32.5% | — |
 DERM | $102M | -6.9 | — | — | 62.8% | -24.4% | -72.6% | -56.8% | — |
 ACLX | $7B | -28.3 | — | — | 70.0% | -1135.6% | -53.4% | -46.2% | — |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
See FBRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FBRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FBRX vs ETON
Side-by-side business, growth, and profitability comparison vs Eton Pharmaceuticals, Inc..
Start ComparisonFBRX — Frequently Asked Questions
Quick answers to the most common questions about buying FBRX stock.
What is Forte Biosciences, Inc.'s P/E ratio?
Forte Biosciences, Inc.'s current P/E ratio is -2.2x. This places it at the 50th percentile of its historical range.
What is Forte Biosciences, Inc.'s ROE?
Forte Biosciences, Inc.'s return on equity (ROE) is -80.8%. The historical average is -78.0%.
Is FBRX stock overvalued?
Based on historical data, Forte Biosciences, Inc. is trading at a P/E of -2.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.